warfarin has been researched along with Cognitive-Dysfunction* in 7 studies
1 review(s) available for warfarin and Cognitive-Dysfunction
Article | Year |
---|---|
[Atrial fibrillation as Risk Factor for Development of Cognitive Function Impairment and Dementia. Potential of Anticoagulant Therapy in Their Prevention].
This article presents an overview of data of Russian and foreign literature on possible associations between cognitive impairment and atrial fibrillation (AF). It includes modern classification of cognitive impairment, mechanisms of the effect of AF on cognitive functions and development of dementia, recommendations for the prevention of cognitive impairment in patients with AF. Special attention is paid to the assessment of cognitive status, and safe anticoagulant therapy, which is a priority in the prevention of cognitive impairment in patients with AF. Analysis of literature showed greater efficacy and safety of drugs from the group of Non-vitamin K Antagonist Oral Anticoagulants (NOAC), rivaroxaban in particular, in comparison with warfarin. Drugs from the NOAC group can be recommended for prevention stroke, cognitive impairment and dementia in elderly patients with AF. Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cognition; Cognitive Dysfunction; Dementia; Humans; Risk Factors; Rivaroxaban; Russia; Warfarin | 2018 |
1 trial(s) available for warfarin and Cognitive-Dysfunction
Article | Year |
---|---|
Rationale and design of the impact of anticoagulation therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard study.
Atrial fibrillation (AF) is associated with a risk for cognitive impairment and dementia, which is more pronounced in patients with a history of clinical stroke. Observational trials suggest that the implementation and quality of long-term anticoagulation impact dementia risk. Emerging evidence suggests that direct oral anticoagulants may improve long-term risk of dementia in AF patients. This manuscript describes the rational and trial design of the the Cognitive Decline and Dementia in Atrial Fibrillation Patients (CAF) Trial. CAF investigates if AF patients randomized to dabigatran etexilate will have long-term higher cognition scores and lower rates of dementia compared in the long term to dose-adjusted warfarin (International Normalized Ratio [INR]: 2.0-3.0). As of 27 February 2019, a total of 120 subjects will be enrolled at one investigational site in the United States and will be followed for 2 years after study enrollment. To date, 97 have been enrolled. The average age is 74.2 years, 53% are male, and 9% had a prior stroke. In this Vanguard study, patients will be followed for 2 years after study enrollment. These prospective, randomized data will inform the understanding of two anticoagulants in AF patients as it relates to risk of cognitive decline and dementia. Cranial imaging and biomarkers collected will assist in understanding mechanisms of brain injury. Topics: Aged; Anticoagulants; Atrial Fibrillation; Cognition; Cognitive Dysfunction; Dabigatran; Dementia; Female; Humans; Incidence; International Normalized Ratio; Male; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Warfarin | 2019 |
5 other study(ies) available for warfarin and Cognitive-Dysfunction
Article | Year |
---|---|
Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Cognitive Dysfunction; Dementia; Humans; Warfarin | 2022 |
Cognitive Decline Over Time in Patients With Systolic Heart Failure: Insights From WARCEF.
This study sought to characterize cognitive decline (CD) over time and its predictors in patients with systolic heart failure (HF).. Despite the high prevalence of CD and its impact on mortality, predictors of CD in HF have not been established.. This study investigated CD in the WARCEF (Warfarin versus Aspirin in Reduced Ejection Fraction) trial, which performed yearly Mini-Mental State Examinations (MMSE) (higher scores indicate better cognitive function; e.g., normal score: 24 or higher). A longitudinal time-varying analysis was performed among pertinent covariates, including baseline MMSE and MMSE scores during follow-up, analyzed both as a continuous variable and a 2-point decrease. To account for a loss to follow-up, data at the baseline and at the 12-month visit were analyzed separately (sensitivity analysis).. A total of 1,846 patients were included. In linear regression, MMSE decrease was independently associated with higher baseline MMSE score (p < 0.0001), older age (p < 0.0001), nonwhite race/ethnicity (p < 0.0001), and lower education (p < 0.0001). In logistic regression, CD was independently associated with higher baseline MMSE scores (odds ratio [OR]: 1.13; 95% confidence interval [CI]: 1.07 to 1.20]; p < 0.001), older age (OR: 1.37; 95% CI: 1.24 to 1.50; p < 0.001), nonwhite race/ethnicity (OR: 2.32; 95% CI: 1.72 to 3.13 for black; OR: 1.94; 95% CI: 1.40 to 2.69 for Hispanic vs. white; p < 0.001), lower education (p < 0.001), and New York Heart Association functional class II or higher (p = 0.03). Warfarin and other medications were not associated with CD. Similar trends were seen in the sensitivity analysis (n = 1,439).. CD in HF is predicted by baseline cognitive status, demographic variables, and NYHA functional class. The possibility of intervening on some of its predictors suggests the need for the frequent assessment of cognitive function in patients with HF. (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction [WARCEF]; NCT00041938). Topics: Aged; Anticoagulants; Aspirin; Cognitive Dysfunction; Female; Fibrinolytic Agents; Heart Failure, Systolic; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Time Factors; Warfarin | 2019 |
Efficacy of Warfarin Anticoagulation and Incident Dementia in a Community-Based Cohort of Atrial Fibrillation.
To study the association between time in therapeutic range (TTR) during warfarin therapy and risk of dementia in a population-based cohort of incident atrial fibrillation (AF).. We conducted an observational population-based study of 2800 nondemented patients with incident AF from January 1, 2000, through December 31, 2010. The association of incident dementia with warfarin therapy and TTR was examined using Cox proportional hazards regression models.. Mean patient age was 71.2 years; 53% were men (n=1495), and warfarin was prescribed to 50.5% (n=1414) within 90 days of AF diagnosis. Incident dementia diagnosis occurred in 357 patients (12.8%) over a mean ± SD follow-up of 5.0±3.7 years. After adjusting for confounders, warfarin therapy was associated with a reduced incidence of dementia (hazard ratio [HR], 0.80; 95% CI, 0.64-0.99). However, only those in the 2 highest quartiles of TTR were associated with lower risk of dementia. A 10% increase in TTR with a 10% reduction in time spent in the subtherapeutic (HR, 0.71; 95% CI, 0.64-0.79) and supratherapeutic (HR, 0.67; 95% CI, 0.57-0.79) ranges were associated with decreased risk of dementia.. In the community, warfarin therapy for AF is associated with a 20% reduction in risk of dementia. Increasing TTR on warfarin is associated with reduced risk of dementia. The risk of dementia was reduced with a reduction in time spent in subtherapeutic and supratherapeutic international normalized ratio range. Effective anticoagulation may prevent cognitive impairment in patients with AF. Topics: Aged; Anticoagulants; Atrial Fibrillation; Cognitive Dysfunction; Cohort Studies; Community-Based Participatory Research; Dementia; Female; Humans; Incidence; International Normalized Ratio; Male; Minnesota; Proportional Hazards Models; Risk Factors; Stroke; Time-to-Treatment; Treatment Outcome; Warfarin | 2018 |
Efficacy of Warfarin Anticoagulation and Incident Dementia: Does Cognitive Impairment Reduce Efficacy?
Topics: Anticoagulants; Atrial Fibrillation; Cognitive Dysfunction; Dementia; Humans; Warfarin | 2018 |
In Reply-Efficacy of Warfarin Anticoagulation and Incident Dementia: Does Cognitive Impairment Reduce Efficacy?
Topics: Anticoagulants; Cognitive Dysfunction; Dementia; Humans; Warfarin | 2018 |